Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Market Data
|
People
|
Events
|
Multimedia
|
Biosimilar EPO and vildagliptin among latest Japanese recommendations
30 November 2009
Ian Haydock

The latest batch of positive product recommendations in Japan includes a biosimilar erythropoietin and two novel antidiabetics, Novartis's DPP-4 inhibitor Equa (vildagliptin) and Novo Nordisk's GLP-1 analogue Victoza (liraglutide).

The recombinant EPO, an epogin kappa product,...



Please Login to read the full article.
 
Not a subscriber? Subscribe to Scrip Request a FREE Trial
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm